The drive for 3D cell culture systems stems from the intensifying need for robust methods for various cell-based assays to be used in drug discovery processes, world over. The rising potential of 3D cell culture in tissue engineering, with respect to in vivo environment, is a notable factor expected to help in the substantial expansion of the market. Compared to other cell-culture methods, 3D cell culture systems have soared in popularity in the recent few years in developed regions, given their amazing potential in oncology research and in discovering regenerative therapies. A new report by Transparency Market Research (TMR), titled “3D Cell Culture Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017–2025”, offers an incisive analysis of market dynamics that sheds light on notable trends and promising avenues over the period of 2017–2025.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35834
The gradually rising application of 3D cell culture in improving the search for potential anticancer drugs is boosting the market. The striking possibility and ease with which 3D cell culture systems can be used to control and monitor a variety of micro-environment parameters of growing cells provides for a compelling proposition for their uptake in the drug discovery processes. The vast utility of 3D cell culture methods in expanding the understanding of organogenesis and cell differentiation is a notable aspect opening promising avenues in the market.
The growing interest of researchers in scaffold-based 3D cell culture technique is likely to significantly fuel the growth of the market. The rising application of scaffold in creating functional implants to be used in clinical and regenerative medicine applications is a notable factor boosting the demand for 3D cell culture. The commercial production of 3D spheroids and their potential in driving high-throughput screening (HTS) applications and basic laboratory research undertaken by biotechnology companies is adding to the attractiveness of scaffold-free platforms, thereby accentuating the growth of the market.
The emergence of 3D cell culture systems as potential substitute for animal prototypes in a range of clinical testing and experiments is accounting for lucrative opportunities for market players. Since the area is relatively new and still emerging, there are potential downsides being encountered in the application of the technique. For instance, the limited ability to control proliferation of cells in in vitro is a significant disadvantage. Nevertheless, constant advances made in 3D cell culture techniques and relentless research in expanding the potential of cell-based assays augur well for the market. The market is also expected to get a robust fillip from the promising potential shown by progenitor and multipotent cells to counter aforementioned limitations.
Some of the key regional markets for 3D cell culture could be North America, Asia Pacific, Latin America, and Europe; of these, Europe and North America are potentially lucrative markets. The prominence of these regional markets can be attributed to the considerable research and development (R&D) investment by public as well as private players in discovering anticancer drugs in various countries, supported by robust healthcare infrastructure. The substantial quantum of governmental funds and grants offered to support these initiatives is also fueling the growth.
On the other hand, Asia Pacific in all its likelihood is expected to rise at a prominent pace, presenting attractive growth avenues. New revenue streams will emanate from the substantially rising demand for advanced cell culture methods in several of the key economies of the region.
Some of the players expected to hold a substantial share in the global 3D cell culture market are QGel, Hamilton Company, Kuraray Co. Ltd., 3D Boitek, Global Cell Solutions, Inc., Synthecon Incorporated, Corning Technologies Pvt Ltd., ReproCELL, Inc., Thermo Fisher Scientific, Inc., Lonza Group, InSphero, Merck & Company, Inc., and Mimetas.